Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income (loss)1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Gilead Sciences Inc. Annual Report.
The Price to Operating Profit (P/OP) ratio exhibits considerable fluctuation over the observed period. Initially, the ratio stood at 25.01 in 2006, demonstrating a significant decrease to 12.16 by 2010. Following this decline, the ratio experienced volatility, with periods of increase and decrease before reaching a low of 5.23 in 2017. More recently, the ratio has shown substantial increases, peaking at 85.65 in 2024, before decreasing to 18.29 in 2025.
- Initial Decline (2006-2010)
- From 2006 to 2010, the P/OP ratio generally decreased. This suggests that while the share price remained relatively stable or experienced modest growth, operating profit per share increased at a faster rate. This could indicate improving operational efficiency or profitability during this period.
- Volatility and Low Point (2011-2017)
- The period between 2011 and 2017 was characterized by fluctuations in the P/OP ratio. Despite some increases, the ratio ultimately reached its lowest point of 5.23 in 2017. This coincided with a period where operating profit per share remained relatively high, while the share price experienced a decline. This suggests investor sentiment may have been unfavorable despite strong operational performance.
- Recent Increases (2018-2024)
- Beginning in 2018, the P/OP ratio began to increase, accelerating significantly in 2024 to reach 85.65. This dramatic increase suggests a substantial rise in the share price relative to operating profit per share. This could be driven by increased investor confidence, market speculation, or anticipation of future growth. The subsequent decrease in 2025 suggests a potential correction or shift in market expectations.
The substantial increase in the P/OP ratio in 2024, followed by a decrease in 2025, warrants further investigation. Understanding the factors driving these changes is crucial for assessing the company’s valuation and future prospects. The earlier period of decline and subsequent volatility suggests a complex relationship between share price and operating profitability, influenced by both internal performance and external market conditions.
Comparison to Competitors
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | |||||||
| Feb 28, 2025 | |||||||
| Feb 23, 2024 | |||||||
| Feb 22, 2023 | |||||||
| Feb 23, 2022 | |||||||
| Feb 25, 2021 | |||||||
| Feb 25, 2020 | |||||||
| Feb 26, 2019 | |||||||
| Feb 27, 2018 | |||||||
| Feb 27, 2017 | |||||||
| Feb 24, 2016 | |||||||
| Feb 25, 2015 | |||||||
| Feb 25, 2014 | |||||||
| Feb 27, 2013 | |||||||
| Feb 23, 2012 | |||||||
| Feb 28, 2011 | |||||||
| Mar 1, 2010 | |||||||
| Feb 27, 2009 | |||||||
| Feb 27, 2008 | |||||||
| Feb 27, 2007 | |||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).